Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Biologic Trials

Miami, Florida

Cancer biologic therapy trials in Miami, FL

34 cancer biologic therapy studies are recruiting participants at sites in Miami as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.

Call (888) 343-5902
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Miami at a glance

  • 34 studies are recruiting at a site in Miami.
  • By phase: Early Phase 1 (1), Phase 1 (1), Phase 1/2 (5), Phase 2 (13), Phase 2/3 (1), Phase 3 (13).
  • By sponsor: industry (15), government (11), university, hospital or other (8).
  • By research area: Lymphoma (13), Lung Cancer (11), Breast Cancer (6), Melanoma (4).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in Miami

Basic details from each study's public record (the 30 most recently updated of 34). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    UM Sylvester Comprehensive Cancer Center at Kendall · University of Miami Miller School of Medicine-Sylvester Cancer Center
    Registry record
    NCT03606967 · updated
  2. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    UM Sylvester Comprehensive Cancer Center at Kendall · University of Miami Miller School of Medicine-Sylvester Cancer Center
    Registry record
    NCT05564377 · updated
  3. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    UM Sylvester Comprehensive Cancer Center at Kendall · University of Miami Miller School of Medicine-Sylvester Cancer Center
    Registry record
    NCT06876714 · updated
  4. Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    BriaCell Therapeutics Corporation
    Study sites
    University Of Miami-SCCC-Miami · University of Miami_SCCC - Kendall
    Registry record
    NCT06072612 · updated
  5. Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

    • Phase 3
    • Ages 18 to 100
    • All sexes
    Sponsor
    Greenwich LifeSciences, Inc.
    Study site
    University of Miami - Sylvester Comprehensive Cancer Center
    Registry record
    NCT05232916 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Miami, FL on ClinicalTrials.gov.

Lung cancer studies recruiting in Miami

  1. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Miami Cancer Institute
    Registry record
    NCT06498635 · updated
  2. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Miami Cancer Institute at Baptist Health, Inc. ( Site 0214)
    Registry record
    NCT06623422 · updated
  3. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    UM Sylvester Comprehensive Cancer Center at Kendall · University of Miami Miller School of Medicine-Sylvester Cancer Center
    Registry record
    NCT06096844 · updated
  4. A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    GlaxoSmithKline
    Study site
    GSK Investigational Site
    Registry record
    NCT07099898 · updated
  5. Safety and Efficacy of OBX-115 in Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Obsidian Therapeutics, Inc.
    Study site
    University of Miami
    Registry record
    NCT06060613 · updated
  6. A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Johnson & Johnson Enterprise Innovation Inc.
    Study site
    University of Miami
    Registry record
    NCT06667908 · updated
  7. A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

    • Phase 3
    • All ages
    • All sexes
    Sponsor
    Pierre Fabre Medicament
    Study site
    University of Miami/Jackson Memorial Hospital (Adults only)
    Registry record
    NCT03394365 · updated
  8. A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1111)
    Registry record
    NCT06780137 · updated
  9. A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

    • Phase 1/2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Iovance Biotherapeutics, Inc.
    Study site
    Sylvester Comprehensive Cancer Center
    Registry record
    NCT05361174 · updated
  10. Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Genelux Corporation
    Study sites
    Bioresearch Partner · University of Miami - Sylvester Comprehensive Cancer Center
    Registry record
    NCT06463665 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Miami, FL on ClinicalTrials.gov.

Melanoma studies recruiting in Miami

  1. SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Immatics US, Inc.
    Study site
    University of Miami - Sylvester Comprehensive Cancer Cente
    Registry record
    NCT06743126 · updated
  2. Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    UM Sylvester Comprehensive Cancer Center at Kendall · University of Miami Miller School of Medicine-Sylvester Cancer Center
    Registry record
    NCT05896839 · updated
  3. ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Immatics US, Inc.
    Study site
    University of Miami Hospital and Clinics
    Registry record
    NCT03686124 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Miami, FL on ClinicalTrials.gov.

Lymphoma studies recruiting in Miami

  1. Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

    • Phase 2
    • Up to 365 days
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University of Miami Miller School of Medicine-Sylvester Cancer Center
    Registry record
    NCT06317662 · updated
  2. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    UM Sylvester Comprehensive Cancer Center at Kendall · University of Miami Miller School of Medicine-Sylvester Cancer Center
    Registry record
    NCT06337318 · updated
  3. Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    UM Sylvester Comprehensive Cancer Center at Kendall · University of Miami Miller School of Medicine-Sylvester Cancer Center
    Registry record
    NCT04840602 · updated
  4. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Nicklaus Children's Hospital
    Registry record
    NCT05675410 · updated
  5. Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Allogene Therapeutics
    Study site
    Miami Cancer Institute at Baptist Health, Inc.
    Registry record
    NCT06500273 · updated
  6. A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

    • Early Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    AIDS Malignancy Consortium
    Study site
    University of Miami Miller School of Medicine
    Registry record
    NCT04139304 · updated
  7. A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • From 366 days, up to 46 years
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University of Miami Miller School of Medicine-Sylvester Cancer Center
    Registry record
    NCT06124157 · updated
  8. Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Izidore Lossos, MD
    Study site
    University of Miami
    Registry record
    NCT06796998 · updated
  9. Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    UM Sylvester Comprehensive Cancer Center at Kendall · University of Miami Miller School of Medicine-Sylvester Cancer Center
    Registry record
    NCT05886036 · updated
  10. Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

    • Phase 3
    • From 365 days, up to 25 years
    • All sexes
    Sponsor
    Children's Oncology Group
    Study sites
    Nicklaus Children's Hospital · University of Miami Miller School of Medicine-Sylvester Cancer Center
    Registry record
    NCT03959085 · updated
  11. DALY II USA/ MB-CART2019.1 for DLBCL

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Miltenyi Biomedicine GmbH
    Study site
    Baptist Health Miami Cancer Institute
    Registry record
    NCT04792489 · updated
  12. CD4CAR for CD4+ Leukemia and Lymphoma

    • Phase 1
    • Ages 12 and older
    • All sexes
    Sponsor
    Huda Salman
    Study site
    University of Miami Sylvester Comprehensive Cancer Center
    Registry record
    NCT03829540 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Miami, FL on ClinicalTrials.gov.

Ask about studies near Miami

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Florida

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.

Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-5902

or send a short form

How should we reach you?

Call